ClinicalTrials.gg
CompletedNCT05109234Updated Oct 22, 2025Results posted

A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

A Phase 3 interventional study of Brivaracetam Film-coated tablet and Brivaracetam oral solution in Childhood Absence Epilepsy and Juvenile Absence Epilepsy, sponsored by UCB Biopharma SRL. Completed at 24 sites in 6 countries. Open to participants aged 2 Years to 26 Years. Per ClinicalTrials.gov, last updated 2025-10-22.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
84
Allocation
Not applicable
Ages
2 Years to 26 Years
Sex
All
01

Study summary

The purpose of the study is to investigate the long-term safety, tolerability and efficacy of brivaracetam in pediatric study participants with childhood absence epilepsy (CAE) or juvenile absence epilepsy (JAE).

02

Conditions studied

  • Childhood Absence Epilepsy
  • Juvenile Absence Epilepsy

Keywords

  • Childhood absence epilepsy
  • Juvenile absence epilepsy
  • Brivaracetam
  • Phase 3
  • Briviact
  • CAE
  • JAE
  • Epilepsy
03

In context

Epilepsy, Absence

24 studies on the registry are indexed under Epilepsy, Absence; 2 are open to participants now.

This study's enrollment of 84 is above the median of 20 across 17 interventional studies indexed under Epilepsy, Absence.

Browse Epilepsy, Absence studies →

Lead sponsor

UCB Biopharma SRL is the lead sponsor of 130 studies on the registry; 18 are open to participants now.

Of its 71 completed or terminated interventional studies of FDA-regulated products, 50 (70%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 26 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who previously participated in N01269 (NCT04666610) and qualify for entry into EP0132 as per N01269 (NCT04666610) protocol with a confirmed diagnosis of childhood absence epilepsy (CAE) or juvenile absence epilepsy (JAE), and for whom a reasonable benefit from long-term administration of brivaracetam (BRV) is expected, in the opinion of the Investigator
  • A sexually active male study participant must agree to use during the treatment period and for at least 2 days, corresponding to the time needed to eliminate study treatment, after the last dose of study treatment and refrain from donating sperm during this period
  • A female study participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies:

    1. The study participant is premenarchal OR
    2. A woman of (WOCBP) who agrees to follow the contraceptive guidance during the treatment period and for at least 2 days after the last dose of study medication, corresponding to the time needed to eliminate study treatment
  • Study participant is capable of and provides consent/assent, and the study participant's parent/legal representative/caregiver provides signed for minor study participants, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol

Exclusion criteria

Exclusion Criteria:

  • Study participant has a history or presence of paroxysmal nonepileptic seizures
  • Study participant has severe medical, neurological, or psychiatric disorders or laboratory values, which could, at the discretion of the Investigator, affect safe participation in the study or would preclude appropriate study participation
  • Study participant has a (ECG) abnormality in the opinion of the Principal Investigator
  • Study participant has hepatic impairment ( Score A, B, or C) based on the Investigator's assessment
  • Study participant has active suicidal ideation prior to study entry as indicated by a positive response ("Yes") to either Question 4 or Question 5 of the Columbia Suicide Severity Rating Scale (C-SSRS) (for study participants 6 years or older) or clinical judgment (for study participants younger than 6 years). The study participant should be referred immediately to a Mental Healthcare Professional
  • Study participant has a lifetime history of suicide attempt (including an active attempt, interrupted attempt, or aborted attempt). The Investigator must immediately refer the study participant to a Mental Healthcare Professional
  • Participant has any medical or psychiatric condition that, in the opinion of the Investigator, could jeopardize or would compromise the study participant's ability to participate in this study
  • Participant has a known fructose intolerance or known to any components of brivaracetam (BRV) or or a drug with similar chemical structure. Note that the tablets contain lactose
  • Study participant has end-stage kidney disease requiring dialysis
  • Concomitant use of carbamazepine, felbamate, gabapentin, oxcarbazepine, phenobarbital, phenytoin, tiagabine, or vigabatrin
  • Study participant has planned participation in any clinical study on an drug or device
  • Study participant has poor compliance with the visit schedule or medication intake in the core study in the opinion of the Investigator
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    Brivaracetam arm

    Subjects in this arm will receive various brivaracetam doses as oral solution or film-coated tablet twice per day.

    Drug: Brivaracetam Film-coated tablet · Drug: Brivaracetam oral solution

Interventions

  • * Pharmaceutical form: Film-coated tablet * Route of administration: Oral use Brivaracetam film-coated tablet \[10, 25 or 50 mg\] will be administered twice per day in equal doses.

  • * Pharmaceutical form: Oral solution * Route of administration: Oral use Brivaracetam oral solution \[10 mg/mL\]) will be administered twice per day in equal doses.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)

    An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication. TEAEs are defined as AEs that had onset on or after the day of first dose of BRV.

    Time frame: From Entry Visit up to 16.32 months (median); min, max exposure to BRV was (0.4, 31.0) months

  2. Percentage of Participants With TEAEs Leading to Discontinuation of Study Treatment

    An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication. TEAEs are defined as AEs that had onset on or after the day of first dose of BRV. Percentage of participants with TEAEs leading to discontinuation were reported.

    Time frame: From Entry Visit up to 16.32 months (median); min, max exposure to BRV was (0.4, 31.0) months

Secondary outcomes

  1. Percentage of Participants With Serious TEAEs

    TEAEs are defined as AEs that had onset on or after the day of first dose of BRV. A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires in patient hospitalization or prolongation of existing hospitalization, is a congenital anomaly or birth defect, results in permanent or significant disability/incapacity, other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above.

    Time frame: From Entry Visit up to 16.32 months (median); min, max exposure to BRV was (0.4, 31.0) months

  2. Percentage of Participants With Study Drug-related TEAEs

    An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication. TEAEs are defined as AEs that had onset on or after the day of first dose of BRV. Drug related AEs are the subset of AEs that the investigator considers as related to the study drug.

    Time frame: From Entry Visit up to 16.32 months (median); min, max exposure to BRV was (0.4, 31.0) months

  3. Percentage of Participants With Absence Seizure Freedom Within 4 Days Prior to or During the 1-hour Electroencephalogram (EEG)

    A 1-hour EEG was performed. The awake hours from the EEG was analyzed for absence seizures. Every 1-hour EEG included hyperventilation as a standard provocation test at the beginning of the EEG. Participant was regarded as not meeting the criteria for absence seizure freedom if they received any permitted antiepileptic drugs including benzodiazepine in the 4 days prior to the EEG or during the EEG. Participants who continue in the study beyond 2 years have their data truncated at Year 2 Month 24 yearly evaluation visit (YEV).

    Time frame: Full Evaluation Visit (6 months), Yearly Evaluation Visit (12 months), Full Evaluation Visit (18 months), Yearly Evaluation Visit (24 months)

  4. Percentage of Participants With Absence Seizure Freedom Based on Daily Seizure Diary Over the Entire Evaluation Period and by 3-month Time Intervals

    During the study, participants kept a diary to record daily seizure activity from entry visit (Visit 1) until the final visit. Each seizure type experienced were recorded. The participant was considered as not meeting the criteria for absence seizure freedom if they use any permitted anti-epileptic drugs at anytime during the period, and/or complete less than 80% of diaries during the period. Evaluation Period includes all daily seizure diary data over the Evaluation Period up to Month 24 YEV, this includes data from the end of Months 22 to 24 up to the Month 24 YEV where this data is truncated. If a participant does not attend the Month 24 YEV then data was truncated at the last day the participant is in the Evaluation Period in the Month 24 YEV window. Participants who continue in the study beyond 2 years have their data truncated at Year 2 Month 24 YEV, or the last day the participant was in the Evaluation Period in the Month 24 YEV window if this visit is not attended.

    Time frame: Months 1-3, Months 4-6, Months 7-9, Months 10-12, Months 13-15, Months 16-18, Months 19-21, Months 22-24 and Entire Evaluation Period (Up to 24 months)

07

Results

Posted Oct 7, 2025
Limitations and caveats
EP0132 enrolled fewer participants than expected (approximately 140) so it was closed prematurely, followed by the initiation of the managed access program EP0225 (NCTID not applicable) and its replacement with the new open-label study EP0224 (NCT06315322).

Participant flow

The study started to enroll participants in March 2022 and concluded in March 2025.

Participant flow — Overall Study
MilestoneChildhood Absence Epilepsy (CAE): BrivaracetamJuvenile Absence Epilepsy (JAE): Brivaracetam
Started6420
Evaluation period (up to 24 months)6420
Completed5014
Not completed146
Withdrew: Adverse event22
Withdrew: Lack of efficacy50
Withdrew: Consent withdrawn by participant (not due to ae)10
Withdrew: Consent withdrawn by parent/guardian (not ae)34
Withdrew: Evacuated from ukraine due to the war20
Withdrew: Missed safety visit; study incomplete per protocol10

Outcome measures

PrimaryPercentage of Participants With Treatment Emergent Adverse Events (TEAEs)

An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication. TEAEs are defined as AEs that had onset on or after the day of first dose of BRV.

Time frame:
From Entry Visit up to 16.32 months (median); min, max exposure to BRV was (0.4, 31.0) months
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)
percentage of participantsChildhood Absence Epilepsy (CAE): BrivaracetamJuvenile Absence Epilepsy (JAE): Brivaracetam
Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)42.255.0
PrimaryPercentage of Participants With TEAEs Leading to Discontinuation of Study Treatment

An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication. TEAEs are defined as AEs that had onset on or after the day of first dose of BRV. Percentage of participants with TEAEs leading to discontinuation were reported.

Time frame:
From Entry Visit up to 16.32 months (median); min, max exposure to BRV was (0.4, 31.0) months
Reported as:
Number · percentage of participants
Percentage of Participants With TEAEs Leading to Discontinuation of Study Treatment
percentage of participantsChildhood Absence Epilepsy (CAE): BrivaracetamJuvenile Absence Epilepsy (JAE): Brivaracetam
Percentage of Participants With TEAEs Leading to Discontinuation of Study Treatment3.110.0
SecondaryPercentage of Participants With Serious TEAEs

TEAEs are defined as AEs that had onset on or after the day of first dose of BRV. A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires in patient hospitalization or prolongation of existing hospitalization, is a congenital anomaly or birth defect, results in permanent or significant disability/incapacity, other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above.

Time frame:
From Entry Visit up to 16.32 months (median); min, max exposure to BRV was (0.4, 31.0) months
Reported as:
Number · percentage of participants
Percentage of Participants With Serious TEAEs
percentage of participantsChildhood Absence Epilepsy (CAE): BrivaracetamJuvenile Absence Epilepsy (JAE): Brivaracetam
Percentage of Participants With Serious TEAEs3.110.0
SecondaryPercentage of Participants With Study Drug-related TEAEs

An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication. TEAEs are defined as AEs that had onset on or after the day of first dose of BRV. Drug related AEs are the subset of AEs that the investigator considers as related to the study drug.

Time frame:
From Entry Visit up to 16.32 months (median); min, max exposure to BRV was (0.4, 31.0) months
Reported as:
Number · percentage of participants
Percentage of Participants With Study Drug-related TEAEs
percentage of participantsChildhood Absence Epilepsy (CAE): BrivaracetamJuvenile Absence Epilepsy (JAE): Brivaracetam
Percentage of Participants With Study Drug-related TEAEs6.310.0
SecondaryPercentage of Participants With Absence Seizure Freedom Within 4 Days Prior to or During the 1-hour Electroencephalogram (EEG)

A 1-hour EEG was performed. The awake hours from the EEG was analyzed for absence seizures. Every 1-hour EEG included hyperventilation as a standard provocation test at the beginning of the EEG. Participant was regarded as not meeting the criteria for absence seizure freedom if they received any permitted antiepileptic drugs including benzodiazepine in the 4 days prior to the EEG or during the EEG. Participants who continue in the study beyond 2 years have their data truncated at Year 2 Month 24 yearly evaluation visit (YEV).

Time frame:
Full Evaluation Visit (6 months), Yearly Evaluation Visit (12 months), Full Evaluation Visit (18 months), Yearly Evaluation Visit (24 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Absence Seizure Freedom Within 4 Days Prior to or During the 1-hour Electroencephalogram (EEG)
percentage of participantsChildhood Absence Epilepsy (CAE): BrivaracetamJuvenile Absence Epilepsy (JAE): Brivaracetam
FEV: 6 months46.470.0
YEV: 12 months42.644.4
FEV: 18 months38.950.0
YEV: 24 months26.718.2
SecondaryPercentage of Participants With Absence Seizure Freedom Based on Daily Seizure Diary Over the Entire Evaluation Period and by 3-month Time Intervals

During the study, participants kept a diary to record daily seizure activity from entry visit (Visit 1) until the final visit. Each seizure type experienced were recorded. The participant was considered as not meeting the criteria for absence seizure freedom if they use any permitted anti-epileptic drugs at anytime during the period, and/or complete less than 80% of diaries during the period. Evaluation Period includes all daily seizure diary data over the Evaluation Period up to Month 24 YEV, this includes data from the end of Months 22 to 24 up to the Month 24 YEV where this data is truncated. If a participant does not attend the Month 24 YEV then data was truncated at the last day the participant is in the Evaluation Period in the Month 24 YEV window. Participants who continue in the study beyond 2 years have their data truncated at Year 2 Month 24 YEV, or the last day the participant was in the Evaluation Period in the Month 24 YEV window if this visit is not attended.

Time frame:
Months 1-3, Months 4-6, Months 7-9, Months 10-12, Months 13-15, Months 16-18, Months 19-21, Months 22-24 and Entire Evaluation Period (Up to 24 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Absence Seizure Freedom Based on Daily Seizure Diary Over the Entire Evaluation Period and by 3-month Time Intervals
percentage of participantsChildhood Absence Epilepsy (CAE): BrivaracetamJuvenile Absence Epilepsy (JAE): Brivaracetam
Months 1-334.435.0
Months 4-639.055.0
Months 7-937.757.9
Months 10-1238.855.6
Months 13-1531.861.1
Months 16-1835.956.3
Months 19-2130.342.9
Months 22-2421.933.3
Entire Evaluation Period (up to 24 months)28.130.0

Adverse events

Collected over From Entry Visit up to 16.32 months (median); min, max exposure to BRV was (0.4, 31.0) months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Childhood Absence Epilepsy (CAE): Brivaracetam0/64 (0%)2/64 (3.1%)15/64 (23.4%)
Juvenile Absence Epilepsy (JAE): Brivaracetam0/20 (0%)2/20 (10%)8/20 (40%)
Most frequent serious events
Most frequent serious events
EventChildhood Absence Epilepsy (CAE): BrivaracetamJuvenile Absence Epilepsy (JAE): Brivaracetam
MeaslesInfections and infestations0/641/20
Generalised tonic-clonic seizureNervous system disorders0/641/20
Status epilepticusNervous system disorders0/641/20
LymphadenitisBlood and lymphatic system disorders1/640/20
Suicidal ideationPsychiatric disorders1/640/20
Most frequent other events
Most frequent other events
EventChildhood Absence Epilepsy (CAE): BrivaracetamJuvenile Absence Epilepsy (JAE): Brivaracetam
Petit mal epilepsyNervous system disorders9/645/20
PyrexiaGeneral disorders4/644/20
HeadacheNervous system disorders3/642/20

Baseline characteristics

The SS consisted of all enrolled study participants who took at least 1 dose of study drug in the long-term follow-up (LTFU) study.

Age, Continuous
Age, Continuous(years)Childhood Absence Epilepsy (CAE): BrivaracetamJuvenile Absence Epilepsy (JAE): BrivaracetamTotal
Mean9.56 ± 2.4913.93 ± 1.6410.60 ± 2.97
Age, Customized
Age, Customized(Participants)Childhood Absence Epilepsy (CAE): BrivaracetamJuvenile Absence Epilepsy (JAE): BrivaracetamTotal
24 months - <12 years53255
12 - <18 years111829
Sex: Female, Male
Sex: Female, Male(Participants)Childhood Absence Epilepsy (CAE): BrivaracetamJuvenile Absence Epilepsy (JAE): BrivaracetamTotal
Female371148
Male27936
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Childhood Absence Epilepsy (CAE): BrivaracetamJuvenile Absence Epilepsy (JAE): BrivaracetamTotal
Race — Asian101
Race — Black or African American505
Race — White572077
Race — Other or Mixed101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Childhood Absence Epilepsy (CAE): BrivaracetamJuvenile Absence Epilepsy (JAE): BrivaracetamTotal
Ethnicity — Hispanic or Latino505
Ethnicity — Not Hispanic or Latino592079
08

Study locations

24 sites
  • Ep0132 115
    Birmingham, Alabama 35233, United States
  • Ep0132 105
    Orange, California 92868-3874, United States
  • Ep0132 110
    Augusta, Georgia 30912, United States
  • Ep0132 100
    New Brunswick, New Jersey 08901, United States
  • Ep0132 109
    Winston-Salem, North Carolina 27157, United States
  • Ep0132 400
    Tbilisi, Georgia
  • Ep0132 401
    Tbilisi, Georgia
  • Ep0132 402
    Tbilisi, Georgia
  • Ep0132 403
    Tbilisi, Georgia
  • Ep0132 405
    Tbilisi, Georgia
  • Ep0132 323
    Messina, Italy
  • Ep0132 321
    Milan, Italy
  • Ep0132 320
    Pavia, Italy
  • Ep0132 322
    Roma, Italy
  • Ep0132 325
    Roma, Italy
  • Ep0132 326
    Verona, Italy
  • Ep0132 562
    Bucharest, Romania
  • Ep0132 560
    Iași, Romania
  • Ep0132 561
    Timişoara, Judeţ Timiş, Romania
  • Ep0132 632
    Bardejov, Slovakia
  • Ep0132 630
    Dubnica nad Váhom, Slovakia
  • Ep0132 600
    Dnipro, Ukraine
  • Ep0132 601
    Dnipro, Ukraine
  • Ep0132 607
    Uzhhorod, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2022 to primary completion in Mar 2025, 35 months.

Results were first posted in Oct 2025, 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2021
First posted
Nov 5, 2021
StartActual
Mar 30, 2022
Primary completionActual
Mar 18, 2025
CompletionActual
Mar 18, 2025
Results first posted
Oct 7, 2025
Last update
Oct 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05109234
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Nov 5, 2021
Start date
Mar 30, 2022
Primary completion
Mar 18, 2025
Completion
Mar 18, 2025
Results posted
Oct 7, 2025
Last update
Oct 22, 2025

Study contacts

UCB Cares
study director · 001 844 599 2273 (UCB)

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brivaracetam

Start the discussion